On June 8, PegBio (Peg Bio Pharmaceuticals-B) rose 8.37% in regular trading, trading at HKD 8.4 per share, with trading volume of approximately HKD 93.36 million.

On the news front, the company announced on June 5 that it received the first commercialization milestone payment of HKD 61 million from Shanghai Tengrui Pharmaceutical under their collaboration agreement for Weipeinatide Injection (Paidakang) in mainland China. This payment marks the partnership entering a substantive execution and full-scale advancement phase. Paidakang is the company's proprietary long-acting GLP-1 receptor agonist approved for the treatment of type 2 diabetes.

The stock has been buoyed by multiple positive catalysts in recent sessions, including CR059 research being selected for an oral presentation at the 62nd EASD Annual Meeting, a board proposal to authorize a buyback of up to 10% of issued H shares pending shareholder approval on June 24, and the inclusion of its core product in the national medical insurance reference drug pre-communication supplementary list, strengthening reimbursement access expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)